Shares of Pfizer Inc. PFE rallied 1.71% to $25.58 Wednesday, on what proved to be an all-around poor trading session for the ...

Pfizer shares fall nearly 5% in a month after weak 2026 guidance, sparking debate over buying the dip or staying cautious.

Promising clinical results in 2026 could set the stage for Pfizer's stock to rebound. However, the company's COVID-19 product ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Pfizer's 2026 revenue midpoint of $61B and EPS midpoint of $2.90 decline YoY, reflecting persisting headwinds. Read more on ...

Pfizer recently announced its guidance for 2026. One thing seems clear: Its financial results won't get much stronger. It ...

Pfizer is a Buy at low valuation but faces a 2030 patent cliff, COVID sales declines, and LOE risks. Click here to read an ...

Pfizer has beaten its earnings per share (EPS) estimates in its past 12 quarters. Beating EPS estimates hasn't always meant positive movements for Pfizer's share price. The stock's low valuation and ...

From a valuation standpoint, Pfizer appears attractive relative to the industry and is trading below its 5-year mean. Going ...

Both Ford and Pfizer have very attractive dividend yields.

Pfizer is in the final stages of a deal to purchase Metsera, offering $47.50 in cash per share and an additional $22.50 if specific performance targets are achieved, as reported by Financial Times.

Pfizer scrapped its own obesity drug candidate, Danuglipron, in early 2025, citing risks of liver enzyme elevations. ・The ...